No Prescription |
 |
 | ||
|
Minirin Nasal Spray DDAVP |
|
| ||
No Prescription » Prescription Drugs 11 » Minirin Nasal Spray DDAVP Desmopressin is used to control the amount of urine your kidneys make. Normally the amount of urine you make is controlled by a certain substance in the body called vasopressin. In people who have "water diabetes" (diabetes insipidus) or certain kinds of head injury or brain surgery the body does not make enough vasopressin. Desmopressin is a man-made form of vasopressin and is used to replace a low level of vasopressin. This medication helps to control increased thirst and too much urination due to these conditions and helps prevent dehydration.Desmopressin products applied in the nose are no longer used to control nighttime bedwetting in children because of the increased risk of developing a serious side effect (a low level of sodium in the blood). Buy Minirin Nasal Spray DDAVP and other Prescription Drugs 11 products online at Medstore. Buy Online at Medstore - Click Here!
About Minirin Nasal Spray DDAVP: Product Type: Prescription Drugs 11 Minirin Nasal Spray ( DDAVP Generic Desmopressin ) Minirin Nasal Spray (DDAVP Generic Desmopressin) DDAVP Generic Desmopressin 10mcg DDAVP Generic Desmopressin Minirin Nasal Spray
View more Prescription Drugs 11 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
